These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 11845923)

  • 21. The distribution problem in economic evaluation: income and the valuation of costs and consequences of health care programmes.
    Donaldson C; Birch S; Gafni A
    Health Econ; 2002 Jan; 11(1):55-70. PubMed ID: 11788982
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term economic benefits attributed to IVF-conceived children: a lifetime tax calculation.
    Connolly MP; Pollard MS; Hoorens S; Kaplan BR; Oskowitz SP; Silber SJ
    Am J Manag Care; 2008 Sep; 14(9):598-604. PubMed ID: 18778175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Age effects in monetary valuation of reduced mortality risks: the relevance of age-specific hazard rates.
    Leiter AM
    Eur J Health Econ; 2011 Aug; 12(4):331-44. PubMed ID: 20376521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Value of a statistical life in road safety: a benefit-transfer function with risk-analysis guidance based on developing country data.
    Milligan C; Kopp A; Dahdah S; Montufar J
    Accid Anal Prev; 2014 Oct; 71():236-47. PubMed ID: 24952315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Against 'Saving Lives': Equal Concern and Differential Impact.
    Chappell RY
    Bioethics; 2016 Mar; 30(3):159-64. PubMed ID: 26132886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Publication selection and the income elasticity of the value of a statistical life.
    Doucouliagos H; Stanley TD; Viscusi WK
    J Health Econ; 2014 Jan; 33():67-75. PubMed ID: 24300998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Are estimates of the value of a statistical life exaggerated?
    Doucouliagos C; Stanley TD; Giles M
    J Health Econ; 2012 Jan; 31(1):197-206. PubMed ID: 22079490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Willingness to pay methods in health care: a sceptical view.
    Cookson R
    Health Econ; 2003 Nov; 12(11):891-4. PubMed ID: 14601152
    [No Abstract]   [Full Text] [Related]  

  • 29. Discounting for health effects in cost-benefit and cost-effectiveness analysis.
    Gravelle H; Smith D
    Health Econ; 2001 Oct; 10(7):587-99. PubMed ID: 11747043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Valuation of road safety effects in cost-benefit analysis.
    Wijnen W; Wesemann P; de Blaeij A
    Eval Program Plann; 2009 Nov; 32(4):326-31. PubMed ID: 19665228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. On optimal length of life.
    Grossman M
    J Health Econ; 1998 Aug; 17(4):499-509. PubMed ID: 10180928
    [No Abstract]   [Full Text] [Related]  

  • 32. Assessing whether there is a cancer premium for the value of a statistical life.
    Viscusi WK; Huber J; Bell J
    Health Econ; 2014 Apr; 23(4):384-96. PubMed ID: 23520055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of the 1990 Hong Kong legislation for restriction on sulfur content in fuel.
    Wong CM; Rabl A; Thach TQ; Chau YK; Chan KP; Cowling BJ; Lai HK; Lam TH; McGhee SM; Anderson HR; Hedley AJ
    Res Rep Health Eff Inst; 2012 Aug; (170):5-91. PubMed ID: 23316618
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Age effects in mortality risk valuation.
    Brey R; Pinto-Prades JL
    Eur J Health Econ; 2017 Sep; 18(7):921-932. PubMed ID: 27928743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estimating an EQ-5D population value set: the case of Japan.
    Tsuchiya A; Ikeda S; Ikegami N; Nishimura S; Sakai I; Fukuda T; Hamashima C; Hisashige A; Tamura M
    Health Econ; 2002 Jun; 11(4):341-53. PubMed ID: 12007165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Valuing life: a plea for disaggregation.
    Sunstein CR
    Duke Law J; 2004 Nov; 54(2):385-445. PubMed ID: 15940845
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Uncertain lifetime, life protection, and the value of life saving.
    Ehrlich I
    J Health Econ; 2000 May; 19(3):341-67. PubMed ID: 10977195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in patients with end-stage renal disease.
    Brennan A; Akehurst R; Davis S; Sakai H; Abbott V
    Value Health; 2007; 10(1):32-41. PubMed ID: 17261114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. On the value of changes in life expectancy.
    Johansson PO
    J Health Econ; 1996 Feb; 15(1):105-13. PubMed ID: 10157424
    [No Abstract]   [Full Text] [Related]  

  • 40. Estimating the Value of Life, Injury, and Travel Time Saved Using a Stated Preference Framework.
    Niroomand N; Jenkins GP
    Accid Anal Prev; 2016 Jun; 91():216-25. PubMed ID: 27015226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.